Virus subversion of immunity: A structural perspective

Current Opinion in Immunology

Volumn 13, Issue 4, 2001, Pages 442-450

  Gewurz, Benjamin E ^a   Gaudet, Rachelle ^b   Tortorella, Domenico ^a   Wang, Evelyn W ^c   Ploegh, Hidde L ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b HARVARD UNIVERSITY   (United States)

^c Surface Logix Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE; CYTOKINE; EPSTEIN BARR VIRUS ANTIGEN; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 18; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1;

ADENOVIRUS; ANTIGEN PRESENTATION; COMPLEMENT ACTIVATION; CYTOMEGALOVIRUS; EPSTEIN BARR VIRUS; HERPES SIMPLEX VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; IMMUNE RESPONSE; MAJOR HISTOCOMPATIBILITY COMPLEX; NONHUMAN; PROTEIN BINDING; PROTEIN STRUCTURE; REVIEW; STRUCTURE ANALYSIS; TARGET CELL; VARICELLA ZOSTER VIRUS; VIRUS IMMUNITY;

AMINO ACID SEQUENCE; ANIMALS; ATP-BINDING CASSETTE TRANSPORTERS; CHEMOKINES; COMPLEMENT ACTIVATION; CYTOKINES; GENES, MHC CLASS II; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; MOLECULAR SEQUENCE DATA; SEQUENCE HOMOLOGY, AMINO ACID; VIRAL ENVELOPE PROTEINS; VIRAL PROTEINS; VIRUS DISEASES; VIRUSES;

EID: 0035425176     PISSN: 09527915     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0952-7915(00)00239-9     Document Type: Review

References (76)

1. Viral mechanisms of immune evasion
2. Host-related immunomodulators encoded by poxviruses and herpesviruses
3. Viral subversion of the immune system
4. Viral immune evasion strategies and the underlying cell biology
5. Interleukin-18 binding protein: A novel modulator of the Th1 cytokine response
6. Determination of the functional epitopes of human interleukin-18-binding protein by site-directed mutagenesis
7. Orthopoxvirus IL-18 binding proteins: Affinities and antagonist activities
8. A poxvirus protein that binds to and inactivates IL-18, and inhibits NK-cell response
9. Vaccinia, cowpox, and camelpox viruses encode soluble gamma interferon receptors with novel broad specificity
10. Effect of IFN-gamma receptor gene deletion on vaccinia virus virulence
11. Vaccinia virus vectors with an inactivated gamma interferon receptor homolog gene (B8R) are attenuated in vivo without a concomitant reduction in immunogenicity
12. The vaccinia virus soluble alpha/beta interferon (IFN) receptor binds to the cell surface and protects cells from the antiviral effects of IFN
13. Orf virus encodes a novel secreted protein inhibitor of granulocyte-macrophage colony-stimulating factor and interleukin-2
14. -/- mice: An overview
15. A single amino acid determines the immunostimulatory activity of interleukin-10
16. Viral IL-10-induced immunosuppression requires Th2 cytokines and impairs APC function within the allograft
17. Crystal structure of Epstein-Barr virus protein BCRF1, a homolog of cellular interleukin-10
18. Human cytomegalovirus harbors its own unique IL-10 homolog (cmvIL-10)
19. Poxvirus genomes encode a secreted, soluble protein that preferentially inhibits beta chemokine activity yet lacks sequence homology to known chemokine receptors
20. Structure of a soluble secreted chemokine inhibitor vCCI (p35) from cowpox virus
21. A broad spectrum secreted chemokine binding protein encoded by a herpesvirus
22. Identification of a γ-herpesvirus selective chemokine binding protein that inhibits chemokine action
23. Regulation of complement activity by vaccinia virus complement-control protein
24. Interaction of vaccinia virus complement control protein with human complement proteins: Factor I-mediated degradation of C3b to iC3b1 inactivates the alternative complement pathway
25. Crystal structure of a complement control protein that regulates both pathways of complement activation and binds heparan sulfate proteoglycans
26. Structure-guided identification of C3d residues essential for its binding to complement receptor 2 (CD21)
27. Conserved surface-exposed K/R-X-K/R motifs and net positive charge on poxvirus complement control proteins serve as putative heparin binding sites and contribute to inhibition of molecular interactions with human endothelial cells: A novel mechanism for evasion of host defense
28. The immunoglobulin fold. Structural classification, sequence patterns and common core
29. Human cytomegalovirus glycoproteins
30. Human cytomegalovirus immediate early glycoprotein US3 retains MHC class I molecules by transient association
31. Sec61-mediated transfer of a membrane protein from the endoplasmic reticulum to the proteasome for destruction
32. Antigen presentation subverted: Structure of the human cytomegalovirus protein US2 bound to the class I molecule HLA-A2
33. Human cytomegalovirus US2 endoplasmic reticulum-lumenal domain dictates association with major histocompatibility complex class I in a locus-specific manner
34. Intracellular surveillance: Controlling the assembly of MHC class I-peptide complexes
35. Association of human class I MHC alleles with the adenovirus E3/19K protein
36. Identification of amino acids within the MHC molecule important for the interaction with the adenovirus protein E3/19K
37. Identification of class I MHC regions which bind to the adenovirus E3-19k protein
38. The selective downregulation of class I major histocompatibility complex proteins by HIV-1 protects HIV-infected cells from NK-cells
39. Kaposi's sarcoma-associated herpesvirus encodes two proteins that block cell surface display of MHC class I chains by enhancing their endocytosis
40. Downregulation of major histocompatibility complex class I molecules by Kaposi's sarcoma-associated herpesvirus K3 and K5 proteins
41. Inhibition of natural killer cell-mediated cytotoxicity by Kaposi's sarcoma-associated herpesvirus K5 protein
42. Can viruses help us to understand and classify the MHC class I molecules at the maternal-fetal interface?
43. Human cytomegalovirus gene products US3 and US6 down-regulate trophoblast class I MHC molecules
44. Structural and functional dissection of human cytomegalovirus US3 in binding major histocompatibility complex class I molecules
45. + T-cells
46. The human cytomegalovirus gene product US6 inhibits ATP binding by TAP
47. The active site of ICP47, a herpes simplex virus-encoded inhibitor of the major histo-compatibility complex (MHC)-encoded peptide transporter associated with antigen processing (TAP), maps to the NH2-terminal 35 residues
48. Stable binding of the herpes simplex virus ICP47 protein to the peptide binding site of TAP
49. Structure of the active domain of the herpes simplex virus protein ICP47 in water/sodium dodecyl sulfate solution determined by nuclear magnetic resonance spectroscopy
50. Combinatorial analysis of the structural requirements of the Escherichia coli hemolysin signal sequence
51. Crystal structure of interleukin-10 reveals the functional dimer with an unexpected topological similarity to interferon gamma
52. Structure of the complex between human T-cell receptor, viral peptide and HLA-A2
53. Crystal structure of an NK-cell immunoglobulin-like receptor in complex with its class I MHC ligand
54. Crystal structure of the human natural killer cell inhibitory receptor KIR2DL1-HLA-Cw4 complex
55. Crystal structure of a lectin-like natural killer cell receptor bound to its MHC class I ligand
56. The functional binding site for the C-type lectin-like natural killer cell receptor Ly49A spans three domains of its major histo-compatibility complex class I ligand
57. The structure of HLA-DM, the peptide exchange catalyst that loads antigen onto class II MHC molecules during antigen presentation
58. *0201/octameric Tax peptide complex with an empty conserved peptide-N-terminal binding site
59. *1501) complexed with a peptide from human myelin basic protein
60. The human cytomegalovirus UL40 gene product contains a ligand for HLA-E and prevents NK-cell-mediated lysis
61. Surface expression of HLA-E, an inhibitor of natural killer cells, enhanced by human cytomegalovirus gpUL40
62. The inhibitory receptor LIR-1 uses a common binding interaction to recognize class I MHC molecules and the viral homolog UL18
63. A mouse cytomegalovirus glycoprotein, gp34, forms a complex with folded class I MHC molecules in the ER which is not retained but is transported to the cell surface
64. A cytomegalovirus glycoprotein re-routes MHC class I complexes to lysosomes for degradation
65. The immunoevasive function encoded by the mouse cytomegalovirus gene m152 protects the virus against T-cell control in vivo
66. The luminal part of the murine cytomegalovirus glycoprotein gp40 catalyzes the retention of MHC class I molecules
67. Inhibition of natural killer cells by a cytomegalovirus MHC class I homologue in vivo
68. Varicella zoster virus retains major histocompatibility complex class I proteins in the Golgi compartment of infected cells
69. Major histocompatibility complex class I molecules are down-regulated at the cell surface by the K5 protein encoded by Kaposi's sarcoma-associated herpesvirus/human herpes-virus-8
70. Inhibition of MHC class I-restricted antigen presentation by gamma 2-herpesviruses
71. Adenovirus E19 has two mechanisms for affecting class I MHC expression
72. HIV-1 Nef protein binds to the cellular protein PACS-1 to downregulate class I major histocompatibility complexes
73. Crystal structure of the conserved core of HIV-1 Nef complexed with a Src family SH3 domain
74. The solution structure of HIV-1 Nef reveals an unexpected fold and permits delineation of the binding surface for the SH3 domain of Hck tyrosine protein kinase
75. The human immunodeficiency virus type 1 (HIV-1) Vpu protein interferes with an early step in the biosynthesis of major histocompatibility complex (MHC) class I molecules
76. Endosomal/lysosomal retention and degradation of major histocompatibility complex class I molecules is induced by myxoma virus